Clinical Trials Logo
  1. Home
  2. Non-melanoma Skin Cancer
  3. NCT05550766
  4. Details
NCT05550766 Clinical Trial

Prognostic Value of RXR-α in Cutaneous Squamous and Basal Cell Carcinoma

Non-melanoma Skin Cancer Clinical Trial

Official title:
Prognostic Value of RXR-α in Cutaneous Squamous and Basal Cell Carcinoma: An Immunohistochemical Study.

Clinical Trial Details — Status: Not yet recruiting

Administrative data
NCT number NCT05550766
Other study ID # Soh-Med-22-09-05
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date December 2022
Est. completion date December 2023

Study information
Verified date September 2022
Source Sohag University
Contact Fatma M.Hamdan
Phone 01000419587
Email fatma.mohammad@med.sohag.edu.eg
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Vitamin D has a crucial role in cancer control and prevention.vitamin D receptor (VDR) and its heterodimer Retinoid X receptor (RXR) are equally important in the cell. This ligand (vitamin D) and receptors (VDR-RXR) complex together triggers downstream DNA damage response in the cell. Retinoid receptors are a superfamily of nuclear receptors. The preferred receptor that attaches to VDR is RXR, with its subunits α, β and γ. RXR α is more frequent in the skin than other tissues, while β occurs in internal organs and γ is frequently related to neural disorders. the investigator hopes to assess prognosis of SCC & BCC by using RXR-α biomarker & attempts to use it in the treatment.

Recruitment information / eligibility
Status Not yet recruiting
Enrollment 50
Est. completion date December 2023
Est. primary completion date September 2023
Accepts healthy volunteers
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: 1. Squamous cell carcinoma and basal cell carcinoma. 2. Incisional & excisional biopsies. 3. All the studied cases include sufficient materials for the immunohistochemical study 4. Complete clinical data Exclusion Criteria: 1. Patients with a history of preoperative chemotherapy and/or radiotherapy. 2. Insufficient or tiny tissue biopsies.

Study Design

Related Conditions & MeSH terms

Locations
Country Name City State
n/a

Sponsors (1)
Lead Sponsor Collaborator
Sohag University

Outcome
Type Measure Description Time frame Safety issue
Primary Prognostic Value of RXR-a in Cutaneous Squamous and Basal Cell Carcinoma immuohistochemical expression of RXR-a in Squamous and Basal Cell Carcinoma One or two days after staining sections with the marker.
See also
  Status Clinical Trial Phase
Not yet recruiting NCT04103658 - NIR and Skin Cancer Margins N/A
Completed NCT01053819 - Can We Miss Pigmented Lesions in Psoriasis Patients? Phase 4
Recruiting NCT03767348 - Study of RP1 Monotherapy and RP1 in Combination With Nivolumab Phase 2
Recruiting NCT05429866 - Immunological Variables Associated to ICI Toxicity in Cancer Patients Phase 2
Active, not recruiting NCT02636569 - Topical Chemoprevention of Skin Cancer Biomarkers Phase 2
Completed NCT02780934 - Comparing Pressure Versus Simple Adhesive Dressing After Mohs Reconstruction N/A
Completed NCT02760160 - Dietary Prevention of Photodamage in Skin With Grapes N/A
Completed NCT02872909 - Randomized Comparison of Low and Conventional Irradiance PDT for Skin Cancer N/A
Withdrawn NCT03327064 - A Biomarker Evaluation Trial of UAB30 in Renal Transplant Recipients at High Risk for Non-melanoma Skin Cancer Phase 1/Phase 2
Completed NCT00342407 - The Incidence of Breast and Other Cancers Among Female Flight Attendants
Terminated NCT04410874 - Imvamune Vaccine for the Treatment of Non-melanoma Skin Cancer Phase 1/Phase 2
Completed NCT03693937 - A Retrospective Evaluation of Superficial Radiation Therapy (SRT) and Non-Melanoma Skin Cancer (NMSC)
Completed NCT04334824 - Hydrochlorothiazide and Risk of Skin Cancer
Recruiting NCT05878288 - Deep sequencIng in Cutaneous Squamous CEll caRciNomas Phase 2
Completed NCT01359735 - Healing Effects of HP802-247 Versus Antibiotic Ointment in Mohs Micrographic Surgery Patients Phase 2
Terminated NCT04348916 - Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors Phase 1
Enrolling by invitation NCT05257486 - Post-market Multi-Center RETRO-Prospective Study to Assess Long-term Clinical Outcomes NMSC Patients Treated With eBx
Withdrawn NCT03757663 - UV Dosimetry Feedback in NMSC Patients N/A
Completed NCT04116983 - DERM NMSC Validation Study
Active, not recruiting NCT06227416 - Skin Tumor Biomarkers by Mass Spectrometry Imaging N/A